Evidence map›Paper›PMID 39945005›Full record

ArticleHaematologica2025

Oncogenic

Sunil K Joshi, Ariane Huang, Janét Pittsenbarger, Ujwal Shinde, Camilo Posso, Paul D Piehowski, Sara J C Gosline, Richard D Press, Marina A Gritsenko, Chelsea Hutchinson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sunil K JoshiDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR.
Ariane HuangKnight Cancer Institute, Oregon Health and Science University, Portland, OR.
Janét PittsenbargerKnight Cancer Institute, Oregon Health and Science University, Portland, OR.
Ujwal ShindeDepartment of Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, OR.
Camilo PossoBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Paul D PiehowskiEnvironmental and Molecular Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Sara J C GoslineBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA; Department of Bioengineering, Oregon Health and Science University, Portland OR.
Richard D PressKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Department of Pathology, Oregon Health and Science University, Portland, OR.
Marina A GritsenkoBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Chelsea HutchinsonBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Karl K WeitzBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Kevin Watanabe-SmithKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Division of Oncological Sciences, Oregon Health and Science University, Portland, OR.
Nicola LongKnight Cancer Institute, Oregon Health and Science University, Portland, OR.
Karin D RodlandKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA; Department of Cell, Development, and Cancer Biology, Oregon Health and Science University, Portland, OR.
Brian J DrukerKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR.
Cristina E TognonKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; Division of Oncological Sciences, Oregon Health and Science University, Portland, OR. tognon@ohsu.edu.

Funding

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2017 to 2026
$13.9M
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaU01CA271412 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRIAN J DRUKER, Paul D Piehowski · 2022 to 2026
$5.8M
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesU01CA217862 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J, TYNER, JEFFREY WALLACE · 2017 to 2021
$5.3M
Mechanisms of venetoclax combination activity in acute myeloid leukemiaR01CA262758 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Stephen E Kurtz, Jeffrey Wallace Tyner · 2021 to 2026
$2.1M
Defining the stromal landscape that sustains AML drug resistanceF30CA239335 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI JOSHI, SUNIL KUMAR · 2019 to 2022
$187k
NCI NIH HHS F30 CA239335NCI NIH HHS R01 CA262758NCI NIH HHS U01 CA217862NCI NIH HHS U01 CA271412NCI NIH HHS U54 CA224019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39945005
PMCPMC12208164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.